Bicara enables access to the thriving innovation ecosystem which accelerates our development of therapies for cancer. Synergies between the Bicara teams in Boston and Bengaluru will pioneer breakthrough innovation.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $273M
Founded date: 2018
Investors 7
| Date | Name | Website |
| 24.02.2024 | Aisling Ca... | aislingcap... |
| 04.04.2023 | Omega Fund... | omegafunds... |
| - | F-Prime Ca... | fprimecapi... |
| 05.04.2022 | Cavendish ... | cavendishf... |
| 03.11.2022 | Red Tree V... | redtreevc.... |
| - | Bioqube Ve... | bioqubeven... |
| - | Eight Road... | eightroads... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.01.2024 | Series C | $165M | - |
| 24.03.2023 | Series B | $108M | Janus Hend... |
Mentions in press and media 14
| Date | Title | Description | Source |
| 10.01.2024 | Bicara Therapeutics Announces Oversubscribed $165 Million Se... | Proceeds to accelerate clinical development of first-in-class bifunctional EGFR/TGF-β inhibitor, BCA... | bioqubeven... |
| 20.12.2023 | Bicara Therapeutics: Clinical-Stage Biotechnology Company Ra... | Bicara Therapeutics – a clinical-stage biotechnology company developing dual-action biologics to eli... | pulse2.com... |
| 13.12.2023 | Bicara Therapeutics Raises $165M in Series C Financing | Bicara Therapeutics, a Boston, MA-based clinical-stage biotechnology company developing dual-action ... | finsmes.co... |
| 12.12.2023 | Bicara Therapeutics Announces Oversubscribed $165 Million Se... | - | fprimecapi... |
| 12.12.2023 | Tome Biosciences goes public today in another biotech megaro... | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech ne... | statnews.c... |
| 12.12.2023 | Bicara nets second nine-digit haul in nine months, raising $... | Venture capitalists and biotech CEOs have been largely speaking with one voice this year with respec... | fiercebiot... |
| 07.07.2023 | Bicara Therapeutics’ First-in-class Bifunctional EGFR/TGF-β ... | Phase 1/1b results to be highlighted in an oral presentation at 2023 ASCO Annual Meeting | bioqubeven... |
| 24.03.2023 | Bicara Therapeutics Announces Oversubscribed $108 Million Se... | Financing will support future studies of lead program BCA101, currently in Phase 1/1b clinical devel... | bioqubeven... |
| 07.03.2023 | Biocon spinout Bicara Therapeutics snags $108 mn in Series B... | Premium Claire Mazumdar, CEO, Bicara Therapeutics Bicara Therapeutics, a biotech firm floated by Kir... | vccircle.c... |
| 06.03.2023 | Bicara Therapeutics Announces Oversubscribed $108 Million Se... | - | fprimecapi... |
Show more